

Docket No.: 21349/5



3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jean-Louis Escary Examiner: Not Yet Assigned

Serial No.: 10/010,749 Group Art Unit: Not Yet Assigned

Filed: December 6, 2001

For: Method for the Determination of at Least One Functional Polymorphism in the Nucleotide Sequence of a Preselected Candidate and Its Applications

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as EXPRESS MAIL #EL 761010819 US in an envelope addressed to the: BOX PATENT APPLICATION, Assistant Commissioner for Patents, Washington, D.C. 20231 on:

By:

Deborah Celeste

Date

1-8-02

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Prior to examining the above-entitled patent application, please make the following amendments.

IN THE CLAIMS:

Please amend claims 21 and 24. Please add new claim 25.

Applicant amends the claims to read as follows:

01/15/2002 NR000042 10010749
01 FC:201
02 FC:203
370.00 OP
45.00 OP

21. A method for treating an individual having a pathology and/or disease correlated to the presence or absence of a mutated allele comprising at least one functional SNP in a gene linked to said pathology and/or disease comprising administering a therapeutically effective amount of a polynucleotide prepared according to claim 17 and a pharmaceutically acceptable carrier.

24. A method for identifying the functional SNP(s) associated with at least one pathology and/or disease or the resistance thereto, comprising analyzing the databank of claim 22 for statistically relevant associations.

25. A method for treating an individual having a pathology and/or disease correlated to the presence or absence of a mutated allele comprising at least one functional SNP in a gene linked to said pathology and/or disease comprising administering a therapeutically effective amount of a polypeptide prepared according to claim 18 and a pharmaceutically acceptable carrier.


Attached hereto as Appendix I is a marked-up version of the claims as amended.

REMARKS

No new matter has been added as a result of the present amendment.

The Examiner is invited and encouraged to telephone the undersigned in furtherance of the prosecution of the present application.

Respectfully submitted,



Mark A. Hofer
Reg. No. 30,068

Brown Rudnick Freed & Gesmer
One Financial Center
Boston, MA 02111
Phone: 617-856-8327
Fax: 617-856-8201
e-mail: mhofer@brfg.com
January 8, 2002

APPENDIX I

21.(Amended) A method for treating an individual having a pathology and/or disease correlated to the presence or absence of a mutated allele comprising at least one functional SNP in a gene linked to said pathology and/or disease comprising administering a therapeutically effective amount of a polynucleotide prepared according to claim 17 [and/or polypeptide prepared according to claim 18] and a pharmaceutically acceptable carrier.

24.(Amended) A method for identifying the functional SNP(s) associated with at least one pathology and/or disease or the resistance thereto, comprising analyzing the databank of claim 22 for statistically relevant associations.

25.(new) A method for treating an individual having a pathology and/or disease correlated to the presence or absence of a mutated allele comprising at least one functional SNP in a gene linked to said pathology and/or disease comprising administering a therapeutically effective amount of a polypeptide prepared according to claim 18 and a pharmaceutically acceptable carrier.